In this case, a diagnosis of ES was initially masked by confirmed APS and thrombocytopenia due to the overlapping presentations of the two syndromes.? Case presentation A 67-year-old Caucasian male with a past medical history of type 2 diabetes mellitus, hypertension, and chronic kidney disease presented with unprovoked DVT of the left lower extremity Ionomycin in March 2013.?Coagulation work-up revealed elevated beta-2 glycoprotein I (2GPI) IgM and cardiolipin IgM antibody titers greater than 99th percentile and repeat titers confirmed the diagnosis of primary APS, and the patient was started on lifelong warfarin. The patients hematological status was further complicated with a diagnosis of immune thrombocytopenia (ITP) after a platelet count of 7?x 109/L and a right lower extremity DVT in 2014; a 40 mg prednisone taper resolved his symptoms. on the differential diagnosis of patients with APS and thrombocytopenia could enhance health outcomes.? strong class=”kwd-title” Keywords: antiphospholipid syndrome, thrombocytopenia, evans syndrome Introduction Evans syndrome (ES) is a rare autoimmune disorder that presents with simultaneous or sequential development of autoimmune hemolytic anemia (AIHA), thrombocytopenia, or immune-mediated neutropenia [1]. Primary antiphospholipid syndrome (APS) is an acquired antibody-mediated disorder characterized by thrombosis causing recurrent fetal demise, stroke, deep vein thrombosis (DVT), or other arterial thrombotic events. Primary APS can also be associated with thrombocytopenia and hemolytic anemia, findings required for a diagnosis of ES [2]. In this case, a diagnosis of ES was initially masked by confirmed APS and thrombocytopenia due to the overlapping presentations of the Ionomycin two syndromes.? Case presentation A 67-year-old Caucasian male with a past medical history of type 2 diabetes mellitus, hypertension, and chronic kidney disease presented with unprovoked DVT of the left lower extremity in March 2013.?Coagulation work-up revealed elevated beta-2 glycoprotein I (2GPI) IgM and cardiolipin IgM antibody titers greater than 99th percentile and repeat titers confirmed the diagnosis of primary APS, and the patient was started on lifelong warfarin. The patients hematological status was further complicated with a diagnosis of immune thrombocytopenia (ITP) after a platelet count of 7?x 109/L and a right lower extremity DVT in 2014; a 40 mg prednisone taper resolved his symptoms. However, relapse occurred in August 2015 with a platelet count of Ionomycin 48 x 109/L. Re-initiation of prolonged prednisone taper resulted in a gradual return of platelets to baseline. In November 2015, the patient was admitted to the hospital for jaundice, low hemoglobin (6.0 g/dl), and laboratory confirmation of warm AIHA. Patient received four units ofpacked red blood cells, 100 mg prednisone, and two treatments of intravenous immunoglobulin therapy.?AIHA in conjunction with a previous history of ITP led to a final diagnosis Ionomycin of ES two years after initial presentation. A 100 mg prednisone taper was initiated, and the platelet count maintained at levels 40 x 109/L with low-dose prednisone (5-10 g) until November 2016 when worsening platelet count required a 20 mg prednisone burst. A steady platelet count of 233 x 109/L was achieved after completing four doses of rituximab therapy in February 2017.?One year later, the patient is doing well on warfarin with Ionomycin normal platelet counts and no episodes of thrombosis or anemia. Discussion ES is a rare disorder that can have a potentially deadly outcome due to the rapid decline in hemoglobin and platelet count. It is a diagnosis of exclusion, requiring a history of Coombs-positive hemolytic anemia, thrombocytopenia, and/or neutropenia. Several autoimmune disorders have been known to occur in conjunction with ES including autoimmune lymphoproliferative syndrome, lupus, Sjogren’s syndrome, and common variable immunodeficiency [3,4].?Additionally, HIV and HCV have been associated with the development of ES, and an infectious work-up is also warranted [5]. Primary APS is an acquired antibody-mediated disorder characterized by thrombosis occurring in the arterial or venous vasculature. The diagnosis of primary APS Rabbit Polyclonal to Collagen III requires two elevated serum studies of 2GPI, lupus anticoagulant, or cardiolipin antibodies obtained 12 weeks [2] apart. Sera is definitely regarded as an incidental locating of AIHA and ITP, but latest research recommend a far more complex immune system dysregulation from the mobile and humoral.